Skip to Main Content

++

INTRODUCTION

++

ceftazidime (sef-tay-zi-deem)

Fortaz, Tazicef

Classification

Therapeutic: anti-infectives

Pharmacologic: third-generation cephalosporins

++
Indications
++

Treatment of the following infections caused by susceptible organisms: skin and skin structure infections, Bone and joint infections, Urinary tract infections, Gynecologic infections, Lower respiratory tract infections, Intra-abdominal infections, Septicemia, Febrile neutropenia, Meningitis.

++
Action
++

Binds to the bacterial cell wall membrane, causing cell death. Therapeutic Effects: Bactericidal action against susceptible bacteria. Spectrum: similar to that of second-generation cephalosporins, but activity against staphylococci is less, while activity against gram-negative pathogens (particularly Pseudomonas aeruginosa) is greater, even for organisms resistant to first- and second-generation agents. Notable is increased action against Citrobacter, Enterobacter, Haemophilus influenzae (including β-lactamase–producing strains), Escherichia coli, Klebsiella pneumoniae, Neisseria meningitidis, Proteus, Providencia, Pseudomonas aeruginosa, Serratia, Moraxella catarrhalis. Not active against methicillin-resistant staphylococci or enterococci.

++
Adverse Reactions/Side Effects
++

CNS: SEIZURES (HIGH DOSES IN PATIENTS WITH RENAL IMPAIRMENT), encephalopathy. GI: PSEUDOMEMBRANOUS COLITIS, abdominal pain, diarrhea, nausea, vomiting. Derm: rashes, pruritus, urticaria. Hemat: bleeding, blood dyscrasias, hemolytic anemia. Local: pain at IM site, phlebitis at IV site. Misc: ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, superinfection, fever.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Watch for seizures; notify physician immediately if patient develops or increases seizure activity.

  • Monitor signs of pseudomembranous colitis, including diarrhea, abdominal pain, fever, pus or mucus in stools, and other severe or prolonged Gi problems (nausea, vomiting, heartburn). Notify physician or nursing staff immediately of these signs.

  • Monitor signs of allergic reactions and anaphylaxis, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough dyspnea) or skin reactions (rash, pruritus, urticaria). Notify physician or nursing staff immediately if these reactions occur.

  • Be alert for signs of encephalopathy, including decreased alertness, lethargy, and incoordination. Notify physician of these signs before they progress to more severe changes in mental status such as dementia, seizures, and coma.

  • Monitor signs of blood dyscrasias including hemolytic anemia (unusual weakness and fatigue, dizziness, jaundice, abdominal pain) and thrombocytopenia (bruising, nose bleeds, bleeding gums, other unusual bleeding). Report these signs to the physician.

  • Monitor injection site for pain, swelling, and irritation. Report prolonged or excessive injection site reactions to the physician.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Employ universal precautions or isolation procedures as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Instruct patient to notify physician immediately of signs of superinfection, including black, furry overgrowth on tongue, vaginal itching or discharge, and loose or foul-smelling stools.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged fever, skin problems (rash, hives, itching), or GI problems (nausea, vomiting, diarrhea, abdominal pain).

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.